The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions

Current Drug Targets

Volumn 5, Issue 6, 2004, Pages 573-579

  Berecz, R ^a,b   Dorado, P ^a,c   De La Rubia, A ^a,d   Caceres M C ^a   Degrell, I ^b   Llerena, A ^a,c  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^d Psychiatric Hospital   (Spain)

Author keywords

CYP2D6; CYP3A4; Metabolism; Pharmacogenetics; Risperidone

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 2D6; DEBRISOQUINE; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ENZYME INDUCING AGENT; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; HISTAMINE RECEPTOR; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PALIPERIDONE; PAROXETINE; RISPERIDONE; RITANSERIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; UNINDEXED DRUG; ZUCLOPENTHIXOL;

AKATHISIA; AUTONOMIC DYSFUNCTION; BODY WEIGHT DISORDER; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL PRACTICE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DYSTONIA; ENZYME ACTIVITY; ENZYME DEFECT; EXTRAPYRAMIDAL SYMPTOM; GENE ACTIVITY; GENE NUMBER; GYNECOMASTIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDIVIDUALITY; METABOLIC PARAMETERS; PARKINSONISM; PHARMACOGENETICS; PSYCHOSIS; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEDATION; SOMNOLENCE; STEADY STATE; TARDIVE DYSKINESIA; WEIGHT GAIN;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 3442875587     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389450043345263     Document Type: Review

References (83)

1. Livingston, M.G. (1994) Lancet, 343(8895), 457-460.
2. Bertilsson, L. and Dahl, M.-L. (1996) CNS Drugs, 5(4), 200-223.
3. Nelson, D.R.; Koymans, L.; Kamataki, T.; Stegeman, JJ.; Feyereisen, R.; Waxman, D.J.; Waterman, M.R.; Gotoh, O.; Coon, M.J.; Estabrook, R.W.; Gunsalus, I.C. and Nebert, D.W. (1996) Pharmacogenetics, 6(1), 1-42.
4. Alván, G.; Bechtel, P.; Iselius, L. and Gundert-Remy, U. (1990) Eur. J. Clin. Pharmacol., 39(6), 533-537.
5. Reviriego, J.; Bertilsson, L.; Carrillo, J.A.; LLerena, A.; Valdivielso, M.J. and Benítez, J. (1993) Eur. J. Clin. Pharmacol., 44(6), 593-595.
6. LLerena, A.; Cobaleda, J.; Martínez, M. and Benítez, J. (1996) Eur. J. Drug Metab. Pharmacokinet., 21(2), 129-138.
7. Dorado, P.; Berecz, R.; Norberto, M.J.; Yasar, U.; Dahl, M.L. and LLerena, A. (2003) Eur. J. Clin. Pharmacol., 59(3), 221-225.
8. De Wildt, S.N.; Kearns, G.L.; Leeder, J.S. and van den Anker, J.N. (1999) Clin. Pharmacokinet., 37(6), 485-505.
9. Cáceres, M.C.; Berecz, R.; González, I.; Dorado, P.; Degrell, I. and LLerena, A. (2003) Abstract to XXV Congreso de la Sociedad Española de Farmacologia, 8-11 October, Cadiz, Spain.
10. LLerena, A.; Berecz, R.; Dorado, P.; de la Garza, C.S.; Norberto, M.J.; Cáceres, M.C. and Gutierrez, J.R. (2003) J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 783(1), 213-219.
11. Mannens, G.; Huang, M.L.; Meuldermans, W.; Hendrickx, J.; Woestenborghs, R. and Heykants, J. (1993) Drug. Metab. Dispos., 21(6), 1134-1141.
12. Janssen, P.A.; Niemegeers, C.J.; Awouters, F.; Schellekens, K.H.; Megens, A.A. and Meert, T.F. (1988) J. Pharmacol. Exp. Ther., 244(2), 685-693.
13. Cohen, L.J. (1994) Pharmacotherapy, 14(3), 253-265.
14. Aravagiri, M. and Marder, S.R. (2000) J. Mass. Spectrom., 35(6), 718-724.
15. Remmerie, B.M.; Sips, L.L.; de Vries, R.; de Jong, J.; Schothius, A.M.; Hooijschuur, E.W. and van de Merbel, N.C. (2003) J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 783(2), 461-472.
16. Maurer, H.H.; Kraemer, T.; Kratzsch, C.; Peters, F.T. and Weber, A.A. (2002) Ther. Drug Monit., 24(1), 117-124.
17. Kratzsch, C.; Peters, F.T.; Kraemer, T.; Weber, A.A. and Maurer, H.H. (2003) J. Mass. Spectrom., 38(3), 283-295.
18. Woestenborghs, R.; Lorreyne, W.; Van Rompaey, F. and Heykants, J. (1992) J. Chromatogr., 583(2), 223-230.
19. Le Moing, J.P.; Edouard, S. and Levron, J.C. (1993) J. Chromatogr., 614(2), 333-339.
20. Price, M.C. and Hoffman, D.W. (1997) Ther. Drug Monit., 19(3), 333-337.
21. Olesen, O.V. and Linnet, K. (1997) J. Chromatogr. B Biomed. Sci. Appl., 698(1-2), 209-216.
22. Aravagiri, M.; Marder, S.R.; Wirshing, D. and Wirshing, W.C. (1998) Pharmacopsychiatry, 31(3), 102-109
23. Balant-Gorgia, A.E.; Gex-Fabry, M.; Genet, C. and Balant, L.P. (1999) Ther. Drug Monit., 21(1), 105-115.
24. Nagasaki, T.; Ohkubo, T.; Sugawara, K.; Yasui, N.; Furukori, H. and Kaneko, S. (1999) J. Pharm. Biomed. Anal., 19(3-4), 595-601.
25. Schatz, D. S. and Saria, A. (2000) Pharmacology, 60(1), 51-56.
26. Avenoso, A.; Facciola, G.; Salemi, M. and Spina, E. (2000) J. Chromatogr. B Biomed. Sci. Appl., 746(2), 173-181.
27. Titier, K.; Deridet, E.; Cardone, E.; Abouelfath, A. and Moore, N. (2002) J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 772(2), 373-378.
28. Heykants, J.; Huang, M.L.; Mannens, G.; Meuldermans, W.; Snoeck, E.; Van Beijsterveldt, L.; Van Peer, A. and Woestenborghs, R. (1994) J. Clin. Psychiatry, 55(Suppl.), 13-17.
29. Huang, M.L.; Van Peer, A.; Woestenborghs, R.; De Coster, R.; Heykants, J.; Janssen, A.A.; Zylicz, Z.; Visscher, H.W. and Jonkman, J.H. (1993) Clin. Pharmacol. Ther., 54(3), 257-268.
30. Prior, T.I.; Chue, P.S.; Tibbo, P. and Baker, G.B. (1999) Eur. Neuropsychopharmacol., 9(4), 301-309.
31. Fang, J.; Bourin, M. and Baker, G.B. (1999) Naunyn-Schmiedeberg's Arch. Pharmacol., 359(2), 147-151.
32. Berecz, R.; LLerena, A.; Kellermann, M.; De La Rubia, A.; Norberto, M.J. and Degrell, I. (1999) Neuropsychopharmacologia Hungarica, 3(1), 23-26.
33. Berecz, R.; LLerena, A.; De La Rubia, A.; Gomez, J.; Kellermann, M.; Dorado, P. and Degrell, I. (2002) Pharmacopsychiatry, 35(6), 231-234.
34. Olesen, O.V.; Licht, R.W.; Thomsen, E.; Bruun, T.; Viftrup, J.E. and Linnet K. (1998) Ther. Drug Monit, 20(4), 380-384.
35. Scordo, M.G.; Spina, E.; Facciola, G.; Avenoso, A.; Johansson, I. and Dahl, M.L. (1999) Psychopharmacology, 147(3), 300-305.
36. Bork, J.A.; Rogers, T.; Wedlund, P.J. and De Leon, J. (1999) J. Clin. Psychiatry, 60(7), 469-476.
37. Roh, H.K.; Kim, C.E.; Chung, W.G.; Park, C.S.; Svensson, J.O. and Bertilsson, L. (2001) Eur. J. Clin. Pharmacol., 57(9), 671-675.
38. Yasui-Furukori, N.; Mihara, K.; Kondo, T.; Kubota, T.; Iga, T.; Takarada, Y.; De Vries, R.; Kaneko, S. and Tateishi, T. (2003) J. Clin. Pharmacol., 43(2), 122-127.
39. Mihara, K.; Kondo, T.; Yasui-Furukori, N.; Suzuki, A.; Ishida, M.; Ono, S.; Kubota, T.; Iga, T.; Takarada, Y.; de Vries, R. and Kaneko, S. (2003) Ther. Drug Monit., 25(3), 287-293.
40. LLerena, A.; Berecz, R.; Dorado, P. and De La Rubia, A. (2003) J. Psychopharmacology, 18(2), 191-195.
41. Spina, E.; Avenoso, A.; Facciola, G.; Salemi, M.; Scordo, M.G.; Giacobello, T.; Madia, A.G. and Perucca, F. (2000) Ther. Drug Monit., 22(4), 481-485.
42. LLerena, A. and Kjivet, R.A. (1994) Br. J. Clin. Pharmacol., 37(6), 531-532.
43. Shin, J.G.; Soukhova, N. and Flockhart, D.A. (1999) Drug Metab. Dispos., 27(9), 1078-1084.
44. Eap, C.B.; Bondolfi, G.; Zullino, D.; Bryois, C.; Fuciec, M.; Savary, L.; Jonzier-Perey, M. and Baumann, P. (2001) Ther. Drug Monit., 23(3), 228-231.
45. Kohnke, M.D.; Griese, E.U.; Stosser, D.; Gaertner, I. and Barth, G. (2002) Pharmacopsychiatry, 35(3), 116-118.
46. Yasui-Furukori, N.; Kondo, T.; Mihara, K.; Suzuki, A.; Inoue, Y.; De Vries, R. and Kaneko, S. (2002) J. Clin. Pharmacol., 42(10), 1083-1088.
47. Tyson, S.C.; Devane, C.L. and Risch, S.C. (1995) Am. J. Psychiatry 152(9), 1401-1402.
48. Raaska, K.; Raitasuo, V. and Neuvonen, P.J. (2002) Eur. J. Clin. Pharmacol., 58(9), 587-591.
49. Benazzi, F. (1999) Pharmacopsychiatry, 32(1), 41.
50. Spina, E.; Avenoso, A.; Scordo, M.G.; Ancione, M.; Madia, A.; Gatti, G. and Perucca, E. (2002) J. Clin. Psychopharmacol., 22(4), 419-423.
51. Bondolfi, G.; Eap, C.B.; Bertschy, G.; Zullino, D.; Vermeulen, A. and Baumann, P. (2002) Pharmacopsychiarty 35(2), 50-56.
52. Spina, E.; Avenoso, A.; Facciola, G.; Scordo, M.G.; Ancione, M. and Madia, A. (2001) Ther. Drug Monit., 23(3), 223-227.
53. Sommers, D.K.; Snyman, J.R.; van Wyk, M.; Blom, M.W.; Huang, M.L. and Levron, J.C. (1997) Int. Clin. Psychopharmacol., 12(3), 141-145.
54. Normann, C.; Lieb, K. and Walden, J. (2002) J. Clin. Psychopharmacol., 22(1), 92-94.
55. Amchin, J.; Zarycranski, W.; Taylor, K.P.; Albano, D. and Klockowski, P.M. (1999) J. Clin. Pharmacol., 39(3), 297-309.
56. Loonen, A.J.; Doorschot, C.H.; Oostelbos, M.C. and Sitsen, J.M. (1999) Eur. Neuropsychopharmacol., 10(1), 51-57.
57. Zoccali, R.; Muscatello, M.R.; Torre, D.L.; Malara, G.; Canale, A.; Crucitti, D.; D'Arrigo, C. and Spina, E. (2003) Pharmacol. Res., 48(4), 411-414.
58. De Leon, J. and Bork, J. (1997) J. Clin. Psychiatry., 58(10), 450.
59. Alfaro, C.L.; Nicolson, R.; Lenanem, M. and Rapoport, J.L. (2000) Ann. Pharmacother., 34(1), 122-123.
60. Spina, E.; Scordo, M.G.; Avenoso, A. and Perucca, E. (2001) J. Clin. Psychopharmacol., 21(1), 108-109.
61. Takahashi, H.; Yoshida, K.; Higuchi, H. and Shimizu, T. (2001) Clin. Neuropharmacol., 24(6), 358-360.
62. Mula, M. and Monaco, F. (2002) Clin. Neuropharmacol., 25(2), 97-100.
63. Ono, S.; Mihara, K.; Suzuki, A.; Kondo, T.; Yasui-Furukori, N.; Furukori, H.; de Vries, R. and Kaneko, S. (2002) Psychopharmacology, 62(1), 50-54.
64. Sanderson, D.R. (1996) J. Clin. Psychiatry, 571(4), 177.
65. Magnuson, T.M.; Keller, B.K. and Burke, W.J. (1998) Am. J. Psychiatry, 155(10), 1458-1459.
66. Liu, H.C.; Lin, S.K. and Sung, S.M. (2002) Psychiatry Clin. Neurosci., 56(4), 479.
67. Zhao, Q.; Xie, C.; Pesco-Koplowitz, L.; Jia, X. and Parier, J.L. (2003) J. Clin. Pharmacol., 43(2), 180-186.
68. Steele, M. and Couturier, J. (1999) Can. J. Clin. Pharmacol., 6(1), 15-17.
69. Fisman, S.; Reniers, D. and Diaz, P. (1996) J. Child. Adolesc. Psychopharmacol., 6(2), 133-138.
70. Kelly, D.V.; Beique, L.C. and Bowmer, M.I. (2002) Ann. Pharmacother., 36(5), 827-830.
71. Jover, F.; Cuadrado, J.M.; Andreu, L. and Merino, J. (2002) Clin. Neuropharmacol., 25(5), 251-253.
72. Leysen, J.E.; Janssen, P.M.; Megens, A.A. and Schotte, A. (1994) J. Clin. Psychiatry, 55(Suppl.), 5-12.
73. Megens, A.A.; Awouters, F.H.; Schotte, A.; Meert, T.F.; Dugovic, C.; Niemegeers, C.J. and Leysen, J.E. (1994) Psychopharmacology, 114(1), 9-23.
74. Nyberg, S.; Dahl, M.L. and Halldin, C. (1995) Psychopharmacology, 119(3), 345-348.
75. Warner, J.P.; Barnes, T.R. and Henry, J.A. (1996) Acia Psychiatr. Scand., 93(4), 311-313.
76. Haverkamp, W.; Breithardt, G.; Camm, A.J.; Janse, M.J.; Rosen, M.R.; Antzelevitch, C.; Escande, D.; Franz, M.; Malik, M.; Moss, A. and Shah, R. (2000) Eur. Heart J., 21(15), 1216-1231.
77. Reilly, J.G.; Ayis, S.A.; Ferrier, I.N.; Jones, S.J. and Thomas, S.H. (2000) Lancet, 355(9209), 1048-1052.
78. Gury, C.; Canceil, O. and Iaria, P. (2000) Encephale, 26(6), 62-72.
79. Ray, W.A.; Meredith, S.; Thapa, P.B.; Meador, K.G.; Hall, K. and Murray, K.T. (2001) Arch. Gen. Psychiatry, 58(12), 1161-1167.
80. Ben-David, J. and Zipes, D.P. (1993) Lancet, 341(8860), 1578-1582.
81. LLerena, A.; Berecz, R.; De La Rubia, A. and Dorado, P. (2002) J. Psychopharmacol., 16(4), 359-362.
82. LLerena, A.; Berecz, R.; De La Rubia, A. and Dorado, P. (2002) Eur. J. Clin. Pharmacol., 58(3), 223-224.
83. LLerena, A.; Berecz, R.; De La Rubia, A.; Norberto, M.J. and Benitez, J. (2000) Ther. Drug Monit., 22(4), 397-401.